Vol. 19/No. 2

Sir Murray F. Brennan, MD, made his reputation—and saved many lives—by pioneering the use of rigorous empirical analysis to evaluate alternative strategies and optimize outcomes in surgical oncology.

Physicians are carefully evaluating potential partnership and referral deals to ensure that whatever they do is perceived as aligned with delivering better, more efficient care.

Oncology drug developers have been able to leverage knowledge about a cause of proliferation— dysregulated activity of the cyclin-dependent kinases (CDKs)—to create a new class of therapy that has rapidly been integrated into the breast cancer treatment paradigm.

Most patients who appear to progress after they begin receiving anticancer immunotherapy will never exhibit a response to therapy.

Doctors from Intermountain Healthcare decided to see if they could improve outcomes of patients placed on expensive machines.

The goal of selecting optimal antiemetic therapy continues to be a moving target with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of chemotherapy-induced nausea and vomiting.

Development of effective therapies for metastatic head and neck cancer has been challenging, and progress has been slow.

Investigators are studying the value of polatuzumab vedotin in patients with intermediate- or high-risk diffuse large B-cell lymphoma.

Researchers have found relationships between the oral microbiome and esophageal cancer; between the vaginal and uterine microbiomes and endometrial cancer; and between the gut microbiome and the efficacy of checkpoint inhibitors.

Recent advances in the understanding of the immune system are paving the way for new and effective approaches to treating cancer.

Pancreatic ductal adenocarcinoma, which is considered incurable, accounts for more than 90% of pancreatic cancer cases.

Fewer than 4% of patients with cancer in the United States participate in clinical trials, the elderly and individuals with clinically relevant comorbidities are strikingly underrepresented in the research portfolio.